NewAmsterdam Pharma Co NV 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934For the transition period fromtoCommission File Number: 001-41562 NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code: +31 (0) 35 206 2971 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 2, 2025, the registrant had 112,270,677 ordinary shares, nominal value €0.12 per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION7 Item 1.Financial Statements (Unaudited)7Condensed Consolidated Balance Sheets7Condensed Consolidated Statements of Comprehensive Income (Loss)8Condensed Consolidated Statements of Shareholders' Equity (Deficit)9Condensed Consolidated Statements of Cash Flows10Notes to Unaudited Condensed Consolidated Financial Statements11Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk25Item 4.Controls and Procedures26 PART II.OTHER INFORMATION28 Item 1.Legal Proceedings28Item 1A.Risk Factors28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds73Item 3.Defaults Upon Senior Securities73Item 4.Mine Safety Disclosures73Item 5.Other Information74Item 6.Exhibits75Signatures76 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements. Forward-lookingstatements provide the Company’s current expectations or forecasts of future events. Forward-looking statementsinclude statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions andother statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,”“could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,”“project,” “should,” “will” and “would,” or similar words or phrases, or the negatives of those words or phrases,may identify forward-looking statements, but the absence of these words does not necessarily mean that astatement is not forward-looking. Examples of forward-looking statements in this Quarterly Report include, butare not limited to, statements regarding the Company’s disclosure concerning its operations, cash flows, financialposition and dividend policy. Forward-looking statements in this Quarterly Report and in any document incorporated by reference in thisQuarterly Report may include, for example, statements about: •the potential liquidity and trading of the Company’s public securities; •the Company’s ability to raise additional capital in sufficient amounts or on terms acceptable to it; •the efficacy and safety of the Company’s product candidate, obicetrapib, as well as potential reimbursement andanticipated market size and market opportunity; •the Company’s dependence on the success of obicetrapib, including the obtaining of regulatory approval tomarket obicetrapib; •the timing, progress and results of clinical trials for obicetrapib, including statements regarding the timing ofinitiation and completion of studies or trials and related preparatory work and the period during which results oftrials will become available and marketing submissions made; •the Company’s ability to attract and retain senior management and key scientific personnel; •the Company’s limited experience in marketing or distributing products; •managing the risks related to the Company’s international oper